Skip to contentI
Insight Molecular Diagnostics Inc.
I
IMDXInsight Molecular Diagnostics Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.14M$1.14Mderived−23.4% vs Q4 2024 Net Income-$22.96M-$22.96MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Insight Molecular Diagnostics Inc. · CIK 1642380 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$496,000−16.6% Operating Incomederived-$23,435,000N/M Operating Cash Flowderived-$5,545,000N/M Free Cash Flowderived-$7,024,000N/M Margins · derivedGross margin43.5%+3.5 pt vs Q4 2024
Operating margin-2057.5%+205.4 pt vs Q4 2024
Net margin-2015.4%+239.8 pt vs Q4 2024
ended Dec 31, 2025 · filed Mar 26, 2026 · 85 d after period end